Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta

Journal of Neurology

Volumn 257, Issue 10, 2010, Pages 1703-1707

  Sena, Armando ^a,b   Bendtzen, Klaus ^c   Cascais, Maria J ^a   Pedrosa, Rui ^b   Ferret Sena, Véronique ^d   Campos, Elisa ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b Centro Hospitalar de Lisboa Central   (Portugal)

^c Rigshospitalet   (Denmark)

^d INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

Author keywords

Apolipoprotein E; Interferon beta; Lipoproteins; Multiple sclerosis; Neutralising antibodies; Tobacco smoking

Indexed keywords

APOLIPOPROTEIN E; BETA INTERFERON; FERRITIN; LEPTIN; NEOPTERIN; NEUTRALIZING ANTIBODY; URIC ACID;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIPOPROTEIN METABOLISM; MULTIPLE SCLEROSIS; PLASMA; PRIORITY JOURNAL; SMOKING; SMOKING HABIT; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANTIBODIES, NEUTRALIZING; APOLIPOPROTEINS E; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS; SMOKING;

EID: 79952198853     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5606-4     Document Type: Article

References (22)

1. Hartung HP, Polman C, Bertolotto A et al (2007) Neutralising antibodies to interferon β in multiple sclerosis: expert panel report. J Neurol 254:827-837
2. Bendtzen K, Kromminga A (2008) Immunogenicity of interferonbeta. In: van de Weert M, Moller EH (eds) Biotechnology: pharmaceutical aspects vol VIII. Immunogenicity of biopharma-ceuticals. Springer, New York, pp 127-136
3. *0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am J Hum Genet 83:219-227
4. Gilli F, Valentino P, Caldano M (2008) Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 71:1940-1947
5. Lo JC, Wang Y, Tumanov AV et al (2007) Lymphotoxin alpha receptor-dependent control of lipid homeostasis. Science 316:285-288
6. Getz SG, Reardon CA (2009) Apoprotein E as a lipid transport and signalling protein in the blood, liver, and artery wall. J Lipid Res S156-S161
7. Giubilei F, Antonini G, De Legges S et al (2002) Blood cholesterol and MRI activity in first episode suggestive of multiple sclerosis. Acta Neurol Scand 106:109-112
8. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H (2009) Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 15:399-402
9. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on diagnosis of multiple sclerosis. Ann Neurol 50:121-127
10. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
11. Roxburgh RH, Seaman SR, Masterman T et al (2005) Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64:1144-1151
12. Rio J, Nos C, Tintoré M et al (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344-352
13. Sorensen PS, Ross C, Clemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1191
14. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
15. Sena A, Couderc Ferret-Sena V et al (2009) Apolipoprotein E polymorphism interacts with cigarette smoking in progression of multiple sclerosis. Eur J Neurol 116:832-837
16. Comabella M, Lunemann JD, Rio J et al (2009) A type I inter-feron signature in monocytes associated with poor response to interferon-beta in multiple sclerosis. Brain 132:3353-3365
17. Carlsson J, Armstrong VW, Reiber H et al (1991) Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chem Acta 196:167-176
18. Feng-Qiao L, Sempowski GD, McKenna SE et al (2006) Apoli-poprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in murine model of multiple sclerosis. J Pharmacol Exp Ther 318:956-965
19. Li L, Thompson PA, Kitchens RL (2008) Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res 49:1782-1793
20. Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M (2007) An association between autoreactive antibodies and anti-interferon - β antibodies in multiple sclerosis. Mult Scler 13:895-899
21. Sena A, Pedrosa R, Graça Morais M (2004) Statins for multiple sclerosis. Lancet 364:412
22. Sapori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2:372-377